Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | F7 | P08709 | 2/20 | 0.48 |
| ▸ | F3 | P13726 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211101 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7212459 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7212475 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7212455 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7217356 | 0.95 | ALDH1A1 (0.54) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7217354 | 0.95 | ALDH1A1 (0.54) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7217351 | 0.95 | ALDH1A1 (0.54) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7217630 | 0.92 | ALDH1A1 (0.61) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7217626 | 0.92 | ALDH1A1 (0.61) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 | |
| SCHEMBL7217623 | 0.92 | ALDH1A1 (0.61) | ALDH1A1MAPTLPAR3SMN1; SMN2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161436-B1 | Polyunsaturated fatty acid derivatives and their use in the treatment of cancer | ARDENIA INVESTMENTS LTD (GI) | 2003-06-25 | — | — | EP | disclosed |
| US-6403554-B2 | Polyunsaturated fatty acid derivatives and their use | ARDENIA INVESTMENTS LTD. (GI) | 2002-06-11 | — | — | US | disclosed |
| EP-1161436-A1 | POLYUNSATURATED FATTY ACID DERIVATIVES AND THEIR USE | Ardenia Investments Ltd. (GI) | 2001-12-12 | — | — | EP | disclosed |
| US-20010037032-A1 | Polyunsaturated fatty acid derivatives and their use | OASMIA PHARMACEUTICAL AB (SE) | 2001-11-01 | — | — | US | disclosed |
| US-6274747-B1 | COMPOUNDS CONTAINING A PHOSPHATE GROUP AND SECONDARY AMIDE GROUP; ANTICANCER AGENTS | ARDENIA INVESTMENTS LTD. (GI) | 2001-08-14 | — | — | US | disclosed |
| WO-2000047589-A1 | POLYUNSATURATED FATTY ACID DERIVATIVES AND THEIR USE | ARDENIA INVESTMENTS LTD. (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037032-A1 | Polyunsaturated fatty acid derivatives and their use | RXRA, RXRB, LPAR2 | ALDH1A1 650/4885MAPT 3417/4885LPAR3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.